Ignite Creation Date:
2025-12-25 @ 1:46 AM
Ignite Modification Date:
2025-12-26 @ 1:12 AM
Study NCT ID:
NCT03003494
Status:
COMPLETED
Last Update Posted:
2019-09-30
First Post:
2016-12-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy
Sponsor:
Boehringer Ingelheim
Organization:
Study Overview
Official Title:
Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy
Status:
COMPLETED
Status Verified Date:
2019-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OTIVACTO
Brief Summary:
The purpose of the study is to measure changes in physical functioning in chronic obstructive pulmonary disease (COPD) patients being treated with Spiolto® Respimat® after approximately 6 weeks in routine clinical practice.
Detailed Description:
Purpose:
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: